Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SiDMAP, a provider of flux-based, metabolic profiling services, has expanded its SiDTox services to enable rapid and specific detection of drug-induced organ toxicity.
Subscribe to our email newsletter
Based on research performed by SiDMAP in collaboration with the Center for Metabolomics at the FDA National Center for Toxicological Research, SiDTox now also includes a cost-effective and non-invasive test which promises to better enable pharmaceutical researchers to rapidly detect drug-induced toxicity prior to organ damage.
Using its proprietary metabolomics technology platform, SiDMAP is able to monitor changes in vital metabolite fluxes in response to drug treatment to determine organ toxicity before structural or morphological damage occurs.
Laszlo Boros, SiDMAP’s chief scientific advisor, said: “Our tracer substrate approach utilizes the accurate assessment and quantification of cross-talk and flux alterations among physiologically vital substrate and product pools and their disruption to provide early indications of the presence and mechanisms of drug-induced toxicity, as seen in the FDA study involving valproic acid.”